Improving quantitative dosimetry in 177Lu-DOTATATE SPECT by energy window-based scatter corrections

Improving quantitative dosimetry in 177Lu-DOTATATE SPECT by energy window-based scatter corrections

Bibliographic Details
Main Authors:	de Nijs, Robin, Lagerburg, Vera, Klausen, Thomas L., Holm, Søren
Format:	Online
Language:	English
Published:	Lippincott Williams & Wilkins 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969156/

Similar Items

A novel planar image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment correlates with haematological toxicity
by: Svensson, Johanna, et al.
Published: (2016)

Method dependence, observer variability and kidney volumes in radiation dosimetry of 177Lu-DOTATATE therapy in patients with neuroendocrine tumours
by: Sandström, Mattias, et al.
Published: (2015)

90Y/177Lu-DOTATATE therapy: survival of the fittest?
by: Brans, Boudewijn, et al.
Published: (2011)

Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
by: Anna Sundlöv, et al.
Published: (2018-07-01)

Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
by: Beauregard, Jean-Mathieu, et al.
Published: (2011)

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
by: Kunikowska, Jolanta, et al.
Published: (2011)

Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals
by: Jill Wevrett, et al.
Published: (2018-08-01)

Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume
by: Svensson, Johanna, et al.
Published: (2016)

IMPROVED PLANAR KIDNEY ACTIVITY CONCENTRATION ESTIMATE BY THE POSTERIOR VIEW METHOD IN 177LU-DOTATATE TREATMENTS
by: Magnander, Tobias, et al.
Published: (2016)

Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment
by: Svensson, Johanna, et al.
Published: (2015)

Quantitative accuracy of 177Lu SPECT reconstruction using different compensation methods: phantom and patient studies
by: Hippeläinen, Eero, et al.
Published: (2016)

Absorbed dose assessment of 177Lu-zoledronate and 177Lu-EDTMP for human based on biodistribution data in rats
by: Yousefnia, Hassan, et al.
Published: (2015)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
by: Aslani, Alireza, et al.
Published: (2015)

Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach
by: Astrid Gosewisch, et al.
Published: (2018-08-01)

Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
by: Repetto-Llamazares, Ada H V, et al.
Published: (2013)

177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
by: Beykan, Seval, et al.
Published: (2016)

Diagnosis of Men-I Syndrome on 68Ga-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE
by: kumar Gupta, Santosh, et al.
Published: (2012)

Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy
by: Ilhan, Harun, et al.
Published: (2016)

Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor
by: Wu, Yin, et al.
Published: (2013)

Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with 177Lu-DOTATATE
by: Basu, Sandip, et al.
Published: (2016)

Development of 177Lu-phytate Complex for Radiosynovectomy
by: Yousefnia, Hassan, et al.
Published: (2013)

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate
by: Bergsma, Hendrik, et al.
Published: (2016)

Preparation and evaluation of Lu-177 phytate Complex for Radiosynovectomy
by: Yousefnia, Hassan, et al.
Published: (2014)

In vivo quantification of 177Lu with planar whole-body and SPECT/CT gamma camera imaging
by: Bailey, Dale L., et al.
Published: (2015)

Radiosynovectomy of the elbow joint synovitis in rheumatoid arthritis treated with Lutetium - 177 labeled hydroxylapatite (Lu-177 HA) particulates; first case report and image of Lu -177 HA in the elbow joint
by: Kamaleshwaran, Koramadai Karuppusamy, et al.
Published: (2014)

Kidney Dosimetry in 177Lu and 90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors
by: Guerriero, F., et al.
Published: (2013)

177Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment
by: Bergmann, Ralf, et al.
Published: (2016)

Metastatic Bone Pain Palliation using 177Lu-Ethylenediaminetetramethylene Phosphonic Acid
by: Alavi, Mehrosadat, et al.
Published: (2015)

Retraction: Preparation and Evaluation of Lu-177 Phytate Complex for Radiosynovectomy
Published: (2016)

In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate
by: Bailey, Dale L, et al.
Published: (2016)

Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical 111In-octreotide SPECT/CT
by: Klausen, Thomas Levin, et al.
Published: (2015)

Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)
by: Arthur J. A. T. Braat, et al.
Published: (2018-06-01)

[177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
by: Baum, Richard P., et al.
Published: (2016)

Multimodal Somatostatin Receptor Theranostics Using [64Cu]Cu-/[177Lu]Lu-DOTA-(Tyr3)octreotate and AN-238 in a Mouse Pheochromocytoma Model
by: Ullrich, Martin, et al.
Published: (2016)

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
by: Ruben Mujica-Mota, et al.
Published: (2018-09-01)

SPECT/CT 90Y-Bremsstrahlung images for dosimetry during therapy
by: Fabbri, C, et al.
Published: (2008)

Myocardial perfusion scintigraphy dosimetry: optimal use of SPECT and SPECT/CT technologies in stress-first imaging protocol
by: Lecchi, M., et al.
Published: (2016)

Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy
by: Larsson, Maria, et al.
Published: (2012)

Anti-tumor Effect of Integrin Targeted 177Lu-3PRGD2 and Combined Therapy with Endostar
by: Shi, Jiyun, et al.
Published: (2014)

Production, Quality Control and Pharmacokinetic Studies of 177Lu-EDTMP for Human Bone Pain Palliation Therapy Trials
by: Bahrami-Samani, Ali, et al.
Published: (2012)